{"product_id":"cst-56750t","title":"CST,  56750T, Glutaminase-1\/GLS1 (E9H6H) Rabbit Monoclonal Antibody","description":"Monoclonal Antibody for studying Glutaminase. Validated for Western Blotting,Immunoprecipitation,Immunohistochemistry (Paraffin). Available in 2 sizes. Highly specific and rigorously validated in-house, Glutaminase-1\/GLS1 (E9H6H) Rabbit Monoclonal Antibody (CST #56750) is ready to ship.\n\n\u003cb\u003eProduct Usage Information\u003c\/b\u003e\nWestern Blotting: 1:1000\nImmunoprecipitation: 1:200\nImmunohistochemistry (Paraffin): 1:200 - 1:800\n\u003cb\u003eStorage\u003c\/b\u003e\nSupplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg\/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 87571 .\n\u003cb\u003eProtocol\u003c\/b\u003e\nAvailable protocols: Western Blotting, Immunoprecipitation, Immunohistochemistry (Paraffin)\n\u003cb\u003eSpecificity \/ Sensitivity\u003c\/b\u003e\nGlutaminase-1\/GLS1 (E9H6H) Rabbit Monoclonal Antibody recognizes endogenous levels of total glutaminase-1\/GLS1 protein. This antibody does not cross-react with glutaminase-2\/GLS2 protein.\nSpecies Reactivity: Human, Monkey\n\u003cb\u003eSource \/ Purification\u003c\/b\u003e\nMonoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly116 of human glutaminase-1\/GLS1 protein.\n\u003cb\u003eBackground\u003c\/b\u003e\nGlutaminase catalyzes the conversion of glutamine to glutamate, the first and rate-limiting step of glutaminolysis (1). Both kidney-type glutaminase (GLS1) and liver-type glutaminase (GLS2) are found in mammals (2). GLS1-mediated glutathione synthesis plays an essential role in redox homeostasis and contributes to increased survival of postimplantation bone cells preconditioned to the hypoxic and ischemic environment in the bone defect site (3). In addition, - -mutant LUAD ( -mutant lung adenocarcinoma) tumors are dependent on increased glutaminolysis (1). Furthermore, recent studies showed higher glutaminolysis and glucose production from glutamine in human primary hepatocytes with gain-of-function missense mutations (4). These findings suggest GLS1 and GLS2 as potential targets in the therapy of bone regeneration and in the treatments of diseases such as cancer and hyperglycemia, respectively (1,3,4).\n\u003cb\u003eAlternate Names\u003c\/b\u003e\nAAD20; CASGID; DKFZp686O15119; EIEE71; FLJ10358; GAC; GAM; GDPAG; GLS; GLS1; GLSK; glutaminase; glutaminase C; Glutaminase kidney isoform, mitochondrial; Glutaminase kidney isoform, mitochondrial 65 kDa chain; Glutaminase kidney isoform, mitochondrial 68 kDa chain; glutaminase, phosphate-activated; K-glutaminase; KGA; KIAA0838; L-glutamine amidohydrolase\n\n\u003cb\u003eSpecification\u003c\/b\u003e\n\nREACTIVITY: H Mk\nSENSITIVITY: Endogenous\nMW (kDa): 55-65\nSource\/Isotype: Rabbit IgG","brand":"CST","offers":[{"title":"Default Title","offer_id":46799829041321,"sku":"56750T","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/cst-56750t","provider":"Iright","version":"1.0","type":"link"}